Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05595395
Other study ID # EK Nr. 1790/2020
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 13, 2023
Est. completion date June 1, 2025

Study information

Verified date October 2023
Source Medical University of Vienna
Contact Manfred Hecking, MD, PhD
Phone 0043-699-10580831
Email manfred.hecking@meduniwien.ac.at
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this pilot study is to overcome the limited evidence on enteral fluid administration in intensive care medicine and to generate data for further hypothesis generation in an exploratory setting. This trial is a prospective, multicenter, randomized, parallel group, open-label study to compare the current standard of practice, the intravenous fluid administration, with a more physiological approach, the enteral fluid administration, in critically ill patients.


Description:

Introduction: The effectiveness and safety of enteral fluid administration in critically ill patients remains unclear. Existing evidence regarding this topic is scarce, but suggests that enteral fluid administration is a safe route of administration. To our knowledge no randomized controlled trial has been conducted investigating this topic. Objectives: The aim of this pilot study is to gather evidence on the impact of enteral fluid replacement on clinical, laboratory and outcome parameters in intensive care patients in order to plan a subsequent larger randomized controlled trial. Clinical outcomes indices evaluated are regurgitation, thirst, serum sodium, mortality, length of mechanical ventilation arterial pressure, urinary volume, body weight, edema, intra-abdominal pressure), changes in bioimpedance spectroscopy-derived markers, fluid overload, renal function tests, liver function tests and SOFA-Scores. Methods: The trial is a prospective, multicenter, randomized, parallel group, open-label study. Patients are going to be recruited and randomized at 3 separate internal medicine intensive care units in Vienna, Austria. A total of 64 patients will be recruited and randomized to receive enteral fluid administration via nasogastric tube or intravenous administration only. Daily visits and evaluation of clinical and radiological fluid status is performed by the attending physician. Regular study visits with Bioimpedance spectroscopy measurements (BIS) to evaluate fluid status are going to be performed Results and conclusions: The ERI study will provide data on potential outcome parameters to plan a subsequent larger randomized control trial for patients receiving enteral fluid therapy in intensive care medicine. Ethics and dissemination: The trial is performed in accordance with the Declaration of Helsinki. It subscribes to the principles outlined in the most recent version of the International Conference on Harmonization on Good Clinical Practice. Approval was obtained from the ethics committee of the Medical University of Vienna (EK number 1790/2020). The study has also been registered in a public clinical trial database (EudraCT Identifier Number 2018-002447-29, clinicaltrialsregister.eu).


Recruitment information / eligibility

Status Recruiting
Enrollment 64
Est. completion date June 1, 2025
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility - Inclusion criteria: - Patient intubated within the last 72h - Age >18 years - Expected required fluid volume may not exceed 4 mL/kg/h (permanently, during at least 24 hours). - Negative pregnancy test in female patients of childbearing potential - Informed consent. For patients that are temporarily unable to consent a - subsequent informed consent must be provided. - Exclusion criteria: - Evidence of severe gastrointestinal disease defined as - Gastrointestinal Failure with > 3 symptoms (see below) or - Lactate >3mmol/L when mesenterial ischemia is a probable cause - Clinical signs of intra-abdominal hypertension and an increase of intra-abdominal pressure of >20 mmHg. - Patients who cannot receive early enteral nutrition due to conditions such as prone positioning in consequence of conditions such as acute respiratory distress syndrome - Pregnancy - Abdominal surgery in the last 3 months (unless all involved physicians, study investigators and caretaking doctors agree that the surgical event does not constitute a limitation for enteral fluid administration) - Postoperative patients with consecutive admission to ICU - Extracorporeal Kidney-Replacement Therapy before intubation - At the discretion of the Investigator Symptoms of Gastrointestinal Failure: - Absent bowel sounds - Bowel distension - Vomiting/regurgitation volume >500 ml - GI bleeding - Diarrhoea (liquid stool >3 times a day) - Distended stomach on ultrasound examination.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Enteral Dose Form
In this intervention arm, fluid substitution is primarily done via enteral administration. The used substance for enteral fluid administered is going to be tap water. Intravenous fluid of choice is going to be "Elomel isoton".
Intravenous Infusion
In this intervention arm, fluid substitution is primarily done via intravenous administration. The used substance for intravenous fluid administered is going to be "Elomel isoton".

Locations

Country Name City State
Austria Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria Vienna
Austria Klinik Favoriten Vienna

Sponsors (2)

Lead Sponsor Collaborator
Medical University of Vienna Klinik Favoriten

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Regurgitation Incidence and extent of regurgitation via the stomach/jejunal probe From the moment of intubation to extubation.
Primary Sodium/Osmolality Differences of serum sodium and serum osmolality From the moment of intubation to extubation.
Primary Thirst Thirst on a zero to 10 numeric rating scale (NRS; worst = 10) On the last study visit (day of extubation)
Primary Days on ventilation Days on ventilation From the moment of intubation to extubation.
Primary 30-day mortality 30-day mortality From the moment of intubation until 30 days after intubation
Secondary Kidney Failure Incidence and extent of kidney failure as well as kidney function From the moment of intubation to extubation.
Secondary SOFA-Score Differences of Sequential Organ Failure Assessment (SOFA) Scores of patients. This score includes PaO2 [mmHg], FiO2 [%], mechanical ventilation [Yes/No], Platelets [/µL], Glascow Coma Scale, Bilirubin [mg/dL], Mean arterial pressure OR administration of vasoactive agents required and creatinine [mg/dL]. The score ranges from 0=best to 24=worst. From the moment of intubation to extubation
Secondary BCM Differences in fluid volume status including Bioimpedance spectroscopy measurements (BIS) using Body Composition Monitor (BCM) From the moment of intubation to extubation
See also
  Status Clinical Trial Phase
Completed NCT05104528 - Non-Invasive Cardiometry and Ultrasound Guided Inferior Vena Cava Collapsibility Index in Assessing Fluid Responsiveness N/A
Completed NCT05070819 - Atrial Natriuretic Peptide in Assessing Fluid Status N/A
Completed NCT04556123 - Management of Fluid Overload in TAVR N/A
Completed NCT04131361 - Inferior Vena Cava Diameter Dependent Colloid Challenge Versus Routine Crystalloid Strategy Transurethral Resection Prostate N/A
Completed NCT04645121 - Carbon Monoxide-based Rebreathing Method and Bioimpedance in Hemodialysis Patients
Completed NCT03505788 - Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Phase 4
Active, not recruiting NCT04882358 - Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion N/A
Not yet recruiting NCT06414759 - Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload Phase 4
Active, not recruiting NCT04334668 - Oral Sodium to Preserve Renal EfficiencY in Acute Heart Failure N/A
Withdrawn NCT01617798 - Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis N/A
Completed NCT04019314 - Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI) N/A
Completed NCT03194750 - Ultrasound Assessment of Volume in Patients on Continuous Dialysis N/A
Recruiting NCT05965934 - Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 Phase 1/Phase 2
Recruiting NCT05240833 - VExUS-guided Fluid Management in Patients With Acute Kidney Injury in the Intensive Care Unit N/A
Completed NCT04623281 - Haemodialysis Outcomes & Patient Empowerment Study 02
Completed NCT03168126 - Advanced Hemodynamic Monitoring in Free Flap Surgery N/A
Recruiting NCT05217342 - PVP-Guided Decongestive Therapy in HF Phase 4
Completed NCT04775576 - Comparison of Conventional Fluid Management Protocol With Targeted Pleth Variability Index (PVI) Monitoring Protocol During Total Abdominal Hysterectomy and Bilateral Salpingooferectomy Operation N/A
Completed NCT05735288 - Haemodialysis Outcomes & Patient Empowerment Study 03
Terminated NCT02769351 - Global rEgistry on decongestioN Therapy Using Less invasivE UltraFiltration